PT-141 is a melanocortin receptor agonist. Kisspeptin is a gnrh-upstream peptide.
They are aimed at different things: PT-141 at libido; Kisspeptin at libido & fertility.
| Comparison | PT-141 (Bremelanotide) bremelanotide · Vyleesi | Kisspeptin kisspeptin-10 · metastin |
|---|---|---|
| How it works | How it works PT-141 works on the brain rather than on blood flow, which makes it fundamentally different from the erectile-dysfunction drugs it gets compared to. | How it works Kisspeptin sits at the very top of the reproductive hormone chain. Everything downstream depends on it, which is why a fault in it causes puberty not to start. |
| What it is | An approved shot that boosts sexual desire through the brain. | A peptide that switches on natural sex-hormone signaling for libido and fertility. |
| Status | FDA approvedFDA-approved | Research only |
| Typical dose | 1.75 mg per dose | — |
| How often | As needed, before activity | As studied |
| Stays active | ~2-3 hours | Not established |
| Dose comes from | FDA drug label | No established range |
| Cycled? | Not cycled, but the label caps it: one dose in 24 hours, and no more than 8 in a month FDA drug label | Should not be given continuously. Response fades within about two weeks of twice-daily dosing Published human study |
| What it does | ||
| Drug class | Melanocortin agonist | GnRH-upstream peptide |
| Used for | An approved shot that boosts sexual desire and arousal by acting on the brain rather than blood flow. It is used for low libido in both women and men. | A peptide that switches on the body's natural sex-hormone signaling, studied for libido, fertility, and hormone support, with a gentler feel than PT-141. |
| Receptors hit | — | — |
| Numbers | ||
| Full dose line | 1.75 mg per dose | Varies (research) |
| Why that cycle | Taken as needed rather than on a schedule, but the label sets a hard ceiling on frequency because of transient blood pressure rises and skin darkening with repeat dosing. That ceiling is the closest thing to a cycling rule here, and it is a real one. | This one has real tolerance data and it points the opposite way from most peptides here. Twice-daily dosing in women caused the response to collapse inside two weeks, with luteinising hormone falling from 23.3 to 1.1 by day 14. Twice-weekly dosing held up far better. The pituitary itself stayed responsive, so the fade happens upstream in the hypothalamus. |
| Weight / effect | Not measured in a trial | Not measured in a trial |
| Chain length | 7 residues | 10 residues |
| Common vial | 10 mg | 5 mg |
| Before you start | ||
| Route | Under the skin (subcutaneous) | Under the skin (subcutaneous) |
| Do not use if | Uncontrolled high blood pressure Known cardiovascular disease Pregnancy | No formal contraindications established |
What separates them
Proof behind the dose. PT-141 has a dose taken straight off an FDA drug label. Kisspeptin has no established dose range at all.
Legal standing. PT-141 is approved or in established clinical use. Kisspeptin is research-only, meaning no regulator has assessed it for use in people.
Staying on it. PT-141 is taken continuously. Kisspeptin is normally run in blocks with breaks, though for this one the block length is convention rather than a tested schedule.
What doesn't differ: They are both taken the same way (under the skin). Neither has a measured effect size from a published trial, so there is no number to rank them on.
What people actually report
PT-141 (Bremelanotide)
- Nausea and a temporary rise in blood pressure are common.
- Chest pain or a severe headache with a racing heart
- An erection lasting more than four hours, which is a medical emergency
Kisspeptin
- Generally well tolerated in trials, but data is limited.
- Signs of an allergic reaction
Side effects are what users and trials report most often, not a complete list. Anything sudden, spreading, or breathing-related is an emergency regardless of which compound caused it.
People also compare
This comparison does not cover cost, long-term safety, or how you personally will respond. Effect figures come from separate trials in different populations and are not always directly comparable to each other. Nothing here is medical advice or a recommendation to use any of these. Talk to a clinician about your own situation.